Varian acquires Transpire dose software

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

Varian Medical Systems announced Aug. 5 that the company acquired dose calculation software produced by Transpire to merge with treatment planning technology.

Transpire, based in Gig Harbor, Wash., developed a software called Acuros, with a modern understanding of tumors in mind. The two companies have been collaborating since 2008. The Acuros algorithm is now integrated into Varian’s radiotherapy systems.

"Acuros software makes it possible to implement highly precise forms of treatment in heterogeneous tissues such as the lung—something other algorithms do not do as well," Jeff Amacker, senior director of clinical solutions for Varian, said in a press release. "Acuros can accomplish this in a workable timeframe, compared with more cumbersome Monte Carlo approaches that are just not used because they take too long."

Varian plans to continue developing Acuros and other software assets acquired in the transaction. Acuros in particular could be used for image guidance and proton therapy treatment planning systems. The acquisition included the migration of a team of Transpire researchers, who now will be working with Varian on these projects. 

 

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.